AR102006A1 - Vacunas recombinantes contra el virus de la fiebre aftosa (fmdv) y sus usos - Google Patents

Vacunas recombinantes contra el virus de la fiebre aftosa (fmdv) y sus usos

Info

Publication number
AR102006A1
AR102006A1 ARP150103061A ARP150103061A AR102006A1 AR 102006 A1 AR102006 A1 AR 102006A1 AR P150103061 A ARP150103061 A AR P150103061A AR P150103061 A ARP150103061 A AR P150103061A AR 102006 A1 AR102006 A1 AR 102006A1
Authority
AR
Argentina
Prior art keywords
fmdv
polypeptide
composition
vaccine
antigen
Prior art date
Application number
ARP150103061A
Other languages
English (en)
Inventor
Reynard Frdric
Widner Justin
Chiang Yu
Wei - Mebatsion Teshome
Christophe Audonnet Jean
Hannas-Djebbara Zahia
Original Assignee
Merial Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Inc filed Critical Merial Inc
Publication of AR102006A1 publication Critical patent/AR102006A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/135—Foot- and mouth-disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Vacunas o composiciones del FMDV, que contienen antígenos del FMDV. Vectores recombinantes que codifican y expresan antígenos, epitopes o inmunógenos del FMDV que se pueden utilizar para proteger a los animales, en particular ovinos, bovinos, caprinos o porcinos, contra el FMDV. Reivindicación 3: La composición o vacuna de la reivindicación 1 ó 2, en donde el antígeno del FMDV es expresado por un vector de baculovirus en células de insecto. Reivindicación 5: La composición o vacuna de cualquiera de las reivindicaciones 1 - 4, en donde el antígeno del FMDV es un polipéptido P1 de tipo silvestre. Reivindicación 6: La composición o vacuna de conformidad con una cualquiera de las reivindicaciones 1 - 5, en donde el antígeno del FMDV es un polipéptido P1 modificado. Reivindicación 17: El vector viral recombinante de la reivindicación 16, en donde el vector viral es un adenovirus. Reivindicación 20: Una cápside vacía del FMDV sustancialmente purificada o una VLP del FMDV expresadas en células de insecto, en donde dicha cápside vacía o la VLP del FMDV comprende un polipéptido que tiene la secuencia que se muestra en la SEQ ID Nº 1, 2, 4, 5, 6, 8, 10, 12, 13, ó 16.
ARP150103061A 2014-09-23 2015-09-23 Vacunas recombinantes contra el virus de la fiebre aftosa (fmdv) y sus usos AR102006A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462054073P 2014-09-23 2014-09-23

Publications (1)

Publication Number Publication Date
AR102006A1 true AR102006A1 (es) 2017-01-25

Family

ID=54256845

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150103061A AR102006A1 (es) 2014-09-23 2015-09-23 Vacunas recombinantes contra el virus de la fiebre aftosa (fmdv) y sus usos

Country Status (17)

Country Link
US (1) US10010605B2 (es)
EP (1) EP3197486A1 (es)
JP (1) JP6931327B2 (es)
KR (1) KR102526219B1 (es)
CN (1) CN107073100B (es)
AP (1) AP2017009834A0 (es)
AR (1) AR102006A1 (es)
AU (2) AU2015320673B2 (es)
BR (1) BR112017005833A8 (es)
CA (1) CA2962225A1 (es)
JO (1) JO3600B1 (es)
MA (1) MA40151B2 (es)
MX (1) MX2017003712A (es)
RU (1) RU2745373C2 (es)
TW (1) TWI733653B (es)
WO (1) WO2016049209A1 (es)
ZA (1) ZA201701851B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108367066B (zh) * 2015-09-10 2023-08-11 台湾地区“中央研究院” 包括类病毒颗粒及新型佐剂的禽流感疫苗组合物
MX2018006347A (es) 2015-11-23 2019-02-20 Merial Inc Proteinas de fusion fmdv y e2 y usos de ellos.
TWI760322B (zh) 2016-01-29 2022-04-11 美商百靈佳殷格翰動物保健美國有限公司 重組腺病毒載體裝載之fmdv疫苗及其用途
US10172933B2 (en) * 2016-10-31 2019-01-08 The United States Of America, As Represented By The Secretary Of Agriculture Mosaic vaccines for serotype a foot-and-mouth disease virus
CN110869047A (zh) * 2017-07-12 2020-03-06 勃林格殷格翰动物保健美国有限公司 塞内卡病毒a免疫原性组合物及其方法
CN108103034B (zh) * 2017-12-15 2022-06-24 云南农业大学动物医学院 同时表达A型、O型和Asia-1型口蹄疫病毒VP1基因重组腺病毒、构建方法及应用
CN108530522B (zh) * 2018-03-14 2021-09-17 中华人民共和国汕头海关 一种重组的OmpK多表位多肽、构建方法及其应用
CN110467654B (zh) * 2018-05-11 2022-08-09 普莱柯生物工程股份有限公司 口蹄疫病毒样颗粒抗原、其制备的疫苗组合物及其制备方法和应用
CN111233984B (zh) * 2018-11-29 2022-08-12 普莱柯生物工程股份有限公司 一种o型口蹄疫病毒样颗粒抗原、及其疫苗组合物、制备方法和应用
WO2020263062A1 (ko) * 2019-06-28 2020-12-30 (주)플럼라인생명과학 구제역 바이러스 백신 조성물
US20230390380A1 (en) * 2020-10-22 2023-12-07 Intervet Inc. Baculovirus expression vector
US20230149528A1 (en) * 2021-08-18 2023-05-18 The United States Of America, As Represented By The Secretary Of Agriculture Development of mosaic vaccines against foot and mouth disease virus serotype o
IL310903A (en) * 2021-08-20 2024-04-01 Intervet Int Bv A method for producing a virus-like particle for foot-and-mouth disease virus
WO2023021167A1 (en) * 2021-08-20 2023-02-23 Intervet International B.V. Method of producing a foot and mouth disease virus virus-like particle
CN117881424A (zh) * 2021-08-20 2024-04-12 珀布赖特研究所 具有双稳定突变的fmdv病毒样颗粒
CN117897170A (zh) * 2021-08-20 2024-04-16 英特维特国际股份有限公司 具有稳定化突变的fmdv病毒样颗粒
KR102513632B1 (ko) * 2021-11-30 2023-03-28 주식회사 왓슨알앤디 구제역 바이러스 유사 입자를 생산하기 위한 백신 플랫폼
US20230255886A1 (en) * 2022-02-16 2023-08-17 Chemical & Schutz High Performance Lubricants, S.A. De C.V. Self-emulsionable mineral oil as a vehicle in vaccines for poultry
CN117210501A (zh) * 2023-09-13 2023-12-12 中国农业科学院兰州兽医研究所 口蹄疫病毒2b蛋白免疫抑制位点突变的重组口蹄疫病毒株的构建
CN117304277B (zh) * 2023-09-26 2024-03-08 中国农业科学院兰州兽医研究所 一种o型口蹄疫病毒vp4蛋白t细胞表位多肽及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA915593B (en) 1990-07-24 1993-03-31 Novagene Inc Herpesvirus-based viral vector which expresses a foot and mounth disease virus epitope on the surface of virus-infected cells and on the surface of virus particles,and vaccine against foot and mounth disease containing the same
FR2810888B1 (fr) * 2000-06-29 2004-07-30 Merial Sas Vaccin contre la fievre aphteuse
EP1773387B1 (en) * 2004-06-25 2013-06-12 Merial Ltd. Avipox recombinants expressing foot and mouth disease virus genes
WO2007059461A2 (en) 2005-11-10 2007-05-24 Genvec, Inc. Adenoviral vector-based foot-and-mouth disease vaccine
CN101270155B (zh) * 2008-05-06 2011-04-27 中国农业科学院兰州兽医研究所 通过耐酸性改造在昆虫中组装口蹄疫病毒空衣壳的方法
US9345759B2 (en) 2010-03-12 2016-05-24 Merial, Inc. Bluetongue virus recombinant vaccines and uses thereof
WO2012158613A1 (en) * 2011-05-13 2012-11-22 Novartis Ag Pre-fusion rsv f antigens
IN2014KN02740A (es) * 2012-06-18 2015-05-08 Novartis Ag
US9738689B2 (en) * 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use

Also Published As

Publication number Publication date
EP3197486A1 (en) 2017-08-02
CN107073100A (zh) 2017-08-18
AP2017009834A0 (en) 2017-03-31
CA2962225A1 (en) 2016-03-31
MA40151B2 (fr) 2022-12-30
BR112017005833A2 (pt) 2018-02-27
TW201625297A (zh) 2016-07-16
KR20170058430A (ko) 2017-05-26
JP2017530124A (ja) 2017-10-12
RU2745373C2 (ru) 2021-03-24
AU2019210537A1 (en) 2019-08-15
WO2016049209A1 (en) 2016-03-31
ZA201701851B (en) 2018-05-30
RU2017113571A (ru) 2018-10-26
RU2017113571A3 (es) 2019-04-22
JO3600B1 (ar) 2020-07-05
AU2015320673A1 (en) 2017-05-11
US20160220659A1 (en) 2016-08-04
AU2015320673B2 (en) 2019-05-02
US10010605B2 (en) 2018-07-03
BR112017005833A8 (pt) 2023-02-14
JP6931327B2 (ja) 2021-09-01
TWI733653B (zh) 2021-07-21
MA40151A1 (fr) 2018-01-31
CN107073100B (zh) 2021-02-26
KR102526219B1 (ko) 2023-04-26
MX2017003712A (es) 2017-06-28

Similar Documents

Publication Publication Date Title
AR102006A1 (es) Vacunas recombinantes contra el virus de la fiebre aftosa (fmdv) y sus usos
AR089039A1 (es) Vectores recombinantes de hvt que expresan antigenos de patogenos de aves y sus usos
CL2018000740A1 (es) Vectores del factor viii del virus adeno-asociado, partículas víricas asociadas y formulaciones terapéuticas que los comprenden
AR110632A1 (es) Vectores del adenovirus canino
MX2021006931A (es) Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos.
AR080515A1 (es) Vacunas recombinantes del virus de la enfermedad del pie y de la boca (fmd1) y sus usos
DOP2012000187A (es) Antigeno ndv recombinante y usos del mismo
AR080313A1 (es) Composiciones de virus de moquillo canino (cdv) recombinante y sus usos
EA201400912A1 (ru) Рекомбинантные поксвирусные векторы, экспрессирующие белки вируса бешенства и ox40, и вакцины, созданные на их основе
UY37100A (es) Vacunas de fmdv vectorizadas con adenovirus recombinantes y usos de las mismas
MX344103B (es) Vacunas de virus herpes vectorizado con virus de enfermedad de newcastle.
CL2015002741A1 (es) Composiciones y métodos para aumentar la respuesta inmune contra patógenos entéricos
CO2017001614A2 (es) Vacuna en vector recombinante de adenovirus aviar serotipo 9
CL2017003341A1 (es) Vectores virales recombinantes que contienen la proteína menor del virus del síndrome reproductor y respiratorio porcino (prrsv) y sus métodos de elaboración y uso
AR108014A1 (es) Vacuna universal para enfermedades virales y método de vacunación
AR109540A1 (es) Moléculas promotoras para expresar antígenos virales
UY36995A (es) Proteínas de fusión de e2 y fmdv y sus usos
MX2015013304A (es) Vacunas de nucleoproteina de la influenza.
AR101840A1 (es) Antígenos del virus del papiloma humano superiores con propiedades inmunológicas superiores, y vacuna que los contiene
EA202092164A1 (ru) Новый ehv с инактивированным ul18 и/или ul8
AR105819A1 (es) Vacunas recombinantes contra el calicivirus felino (fcv) y sus usos
UY36328A (es) Vacunas de fmdv recombinante y usos de las mismas
NZ747030A (en) Fmdv recombinant vaccines and uses thereof

Legal Events

Date Code Title Description
FG Grant, registration